Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556095 | 0.95 | SMN1; SMN2 (0.50) | LTA4HSMN1; SMN2MAPK1CYSLTR2CYSLTR1 | |
| SCHEMBL9000712 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPK1 | |
| SCHEMBL5847824 | 0.83 | LTA4H (0.48) | LTA4HSMN1; SMN2MAPK1CYSLTR2CYSLTR1 | |
| SCHEMBL5555174 | 0.83 | GAA (0.55) | SMN1; SMN2MAPK1MAPT | |
| SCHEMBL13450152 | 0.83 | MEN1 (0.51) | LTA4HSMN1; SMN2MAPK1CYSLTR2CYSLTR1 | |
| SCHEMBL19474670 | 0.81 | LTA4H (0.53) | LTA4HSMN1; SMN2CYSLTR2CYSLTR1MAPT | |
| SCHEMBL6185341 | 0.81 | TAS1R3 (0.51) | SMN1; SMN2MAPK1MAPT | |
| SCHEMBL20484981 | 0.81 | ACACB (0.50) | SMN1; SMN2MAPK1MEN1KMT2ATDP1 | |
| SCHEMBL1284955 | 0.80 | LTA4H (0.52) | LTA4HSMN1; SMN2CYSLTR2CYSLTR1MAPT | |
| SCHEMBL1285180 | 0.80 | LTA4H (0.52) | LTA4HSMN1; SMN2CYSLTR2CYSLTR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2003-11-06 | — | — | US | disclosed |
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | LTA4H 4593/4885SMN1; SMN2 2812/4885MAPK1 3917/4885 |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | LTA4H 4500/4885SMN1; SMN2 3189/4885MAPK1 3745/4885 |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | LTA4H 4500/4885SMN1; SMN2 3189/4885MAPK1 3745/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | LTA4H 4593/4885SMN1; SMN2 2812/4885MAPK1 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.